Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DB289 for Stage I African Trypanosomiasis
NCT00802594Phase 2Completed
- Sponsor
- Immtech Pharmaceuticals, Inc.
- Start
- Aug 2001
- Primary completion
- Aug 2002
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, open-label, single-arm trial of pafuramidine in African trypanosomiasis (HAT), sponsored by Immtech Pharmaceuticals, Inc. Primary endpoints: Parasitological cure 24 hours after completion of treatment at Day 7 and Rate of occurrence of Grade 3 or higher adverse events at Day 12. Started Aug 2001; status: completed.
02
Drugs
pafuramidine
03
Conditions
African trypanosomiasis (HAT)
Beyond the preview
Go deeper on NCT00802594.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00802594.